Open-house discount agreements for original medicines 2024-10 – Tiotropium bromide (Spiriva Respimat, ATC: R03BB04)

Summary

The tender concerns a discount agreement with German health insurer TK for the original medicine Spiriva Respimat containing tiotropium bromide. This is an open-house procedure: agreements are concluded with all eligible pharmaceutical companies on uniform terms, with no individual negotiations and no exclusivity for any partner. Companies may join at any time while the procedure is open. Due to intellectual property rights, participation and contract documents are available only to companies that market the specified medicine or can credibly demonstrate their intention to market it during the contract period. The notice states that the contract may run for up to 24 months from 1 December 2024 and end no later than 30 November 2026, while also stating that the procedure has been extended until 30 November 2028. If the patent expires earlier, the contract ends at the end of the month in which the patent expires. Check the official tender documents for the detailed participation and contract terms.